Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib in NTRK/ROS1/ALK+ solid tumors
NCT02097810Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of entrectinib in solid tumor, sponsored by Roche. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started Jul 2014; status: completed.
02
Drugs
entrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02097810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097810.